Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea

被引:0
|
作者
Jung Wan Park
Hyungmin Lee
Jung Wook Kim
Bongyoung Kim
机构
[1] Korea Centers for Disease Control and Prevention,Department of Healthcare
[2] Asan Medical Center,Associated Infection Control
[3] University of Ulsan College of Medicine,Department of Infectious Diseases
[4] Center for Infectious Diseases Research,Division of Antimicrobial Resistance
[5] Korea National Institute of Health,Department of Internal Medicine
[6] Korea Centers for Disease Control and Prevention,undefined
[7] Hanyang University College of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study was to describe the characteristics of infections with Staphylococcus aureus with reduced vancomycin susceptibility (SARVS) including vancomycin-intermediate S. aureus (VISA) in South Korea, using data from the national sentinel surveillance system during 2014–2016. A total of 66 patients infected or colonized with SA-RVS were reported using the sentinel surveillance system. Among them, VISA was confirmed in 14 isolates (21.2%) and no vancomycin-resistant S. aureus (VRSA) was detected. Most of patients had any kind of indwelling devices (81.8%, 54/66) and underwent surgical procedures in the previous 6 months (84.8%, 56/66). Patients who admitted to an intensive care unit (ICU) in the previous 3 months were 68.2% (45/66). Furthermore, patients who used vancomycin or had MRSA in the previous 1 month were 54.5% (36/66) and 59.1% (39/66), respectively. Upon review of the medical records, 54.5% (36/66) of patients were classified as having SA-RVSassociated infection and 30-day mortality was 19.4% (7/36). Our findings revealed that there was no VRSA in South Korea. SA-RVS including VISA existed particularly in patients who had indwelling devices, history of surgical procedure, and history of ICU admission.
引用
收藏
相关论文
共 50 条
  • [21] Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea
    Kim, HB
    Park, WB
    Lee, KD
    Choi, YJ
    Park, SW
    Oh, MD
    Kim, EC
    Choe, KW
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (06) : 2279 - 2281
  • [22] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638
  • [23] Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
    Zhanel, George G.
    Voth, Dylan
    Nichol, Kim
    Karlowsky, James A.
    Noreddin, Ayman M.
    Hoban, Daryl J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) : 364 - 369
  • [24] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [25] The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus
    Hort, Michael
    Bertsche, Ute
    Nozinovic, Senada
    Dietrich, Alina
    Schroetter, Anne Sophie
    Mildenberger, Laura
    Axtmann, Katharina
    Berscheid, Anne
    Bierbaum, Gabriele
    MICROBIOLOGY SPECTRUM, 2021, 9 (02):
  • [26] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [27] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [28] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
    Chapman, Jenelle E.
    George, Shilpa E.
    Wolz, Christiane
    Olson, Michael E.
    INFECTION GENETICS AND EVOLUTION, 2024, 117
  • [29] DISSEMINATED INFECTION WITH VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS (VISA) IN A 37-YEAR-OLD
    Heller, David
    Sisson, Stephen
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 : S471 - S472
  • [30] The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA
    Howden, Benjamin P.
    Peleg, Anton Y.
    Stinear, Timothy P.
    INFECTION GENETICS AND EVOLUTION, 2014, 21 : 575 - 582